Oric Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $1.37B
- P/E (TTM)
- –
- Dividend yield
- –
About Oric Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that develops therapies to overcome cancer resistance mechanisms. The company focuses on three therapeutic areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. Its clinical-stage pipeline features rinzimetostat, an allosteric inhibitor targeting the polycomb repressive complex 2 for advanced prostate cancer, and enozertinib, an oral inhibitor targeting specific epidermal growth factor receptor mutations in non-small cell lung cancer. Because its product candidates remain under clinical investigation, the company serves cancer patients with advanced solid tumors through clinical trials rather than commercial product sales.
The company maintains its principal executive offices in South San Francisco, California. Its clinical research and development activities span the United States and South Korea, supported by clinical trial collaborations with multinational pharmaceutical partners including Johnson & Johnson and Bayer.
Summary of the business section of Oric Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Oric Pharmaceuticals, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 240 E. Grand Ave., 2nd Floor 94080
- Phone
- (650) 388-5600
- Website
- oricpharma.com
- Employees
- 104, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, California
Stock & identifiers
- Ticker
- ORIC
- Exchange
- Nasdaq
- IPO date
- Apr 24, 2020
- Shares outstanding
- 104M, Jul 27, 2026
- Public float
- $862.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer
- SEC CIK
- 1796280
- CUSIP
- 68622P109
- ISIN
- US68622P1093
- LEI
- 54930033FJRNEYBW0L25
- EIN
- 47-1787157
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jacob Chacko | PRESIDENT AND CEO, Director | 581,711 |
| Dominic Piscitelli | Chief Financial Officer | 83,228 |
| Pratik S. Multani | Chief Medical Officer | 68,149 |
| Richard A. Heyman | Director | 244,972 |
| Mardi Dier | Director | 0 |
| Steven L. Hoerter | Director | – |
| Lori Anne Kunkel | Director | 84,200 |
| Angie You | Director | 28,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jacob M. Chacko, M.D. | $5.57M | $5.69M | $2.26M | $89 | – |
| FY2024 Jacob M. Chacko, M.D. | $5.28M | $4.27M | $2.21M | $88 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 104 full-time employees, of which 76 were engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 24, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 20, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |